Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 96.39B -13.6% |
| Revenue (ttm) | 47.35B +8.2% |
| Net Income | 7.56B +19.9% |
| EPS | 6.20 +23.0% |
| Shares Out | 1.21B |
| PE Ratio | 20.13 |
| Forward PE | 9.24 |
| Dividend | 4.12 (5.26%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 2,411,779 |
| Average Volume | 2,312,556 |
| Open | 78.28 |
| Previous Close | 78.32 |
| Day's Range | 77.91 - 80.09 |
| 52-Week Range | 74.85 - 98.36 |
| Beta | 0.32 |
| RSI | 48.55 |
| Earnings Date | Apr 23, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsNews
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Annual General Meeting of April 29, 2026 Belén Garijo appointed as Director and Chief Executive Officer of Sanofi Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened on Apri...
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%
Several stocks with market capitalizations above $100 billion just made notable dividend announcements. These names are among the largest in their respective industries, and despite widely differing p...
Sanofi Prices EUR 2.3 Bln Notes Offering Across Three Tranches
(RTTNews) - Sanofi (SNY), a biopharmaceutical company, announced that it has priced its offering of 2.3 billion Euros of notes across 3 tranches. Sanofi intends to use the net proceeds of the offering...
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery
Some shareholders are waiting for healthcare stocks to rebound. As they wait, some companies pay out dividends with meaningful yields that make that waiting easier.
Sanofi: Sanofi successfully prices 2.3 billion of bond issue
Sanofi successfully prices 2.3 billion of bond issue Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches: €1,000 million...
Press Release: Sanofi successfully prices 2.3 billion of bond issue
Sanofi successfully prices 2.3 billion of bond issue Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches: €1,000 million...
Sanofi (SNY) Gains EMA's Support for Multiple Sclerosis Treatment
Sanofi (SNY) Gains EMA's Support for Multiple Sclerosis Treatment
Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It's A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia
NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multi...
Weekly Buzz: Sanofi, REGN Get FDA Nod; It's A No For ABBV, GRCE; Eli Lilly Acquires Kelonia
NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multi...
Sanofi's Cenrifki Gets Positive CHMP Nod For Secondary Progressive Multiple Sclerosis Treatment
PARIS (dpa-AFX) - Sanofi SA (SNY) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Cenrifki for treating secondary progress...
Sanofi: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Recommendation based on the HERCULES phase 3 study which...
Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Recommendation based on the HERCULES phase 3 study which dem...
Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments
Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments
Q1 2026 Sanofi SA Earnings Call Transcript
Q1 2026 Sanofi SA Earnings Call Transcript
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat
French drugmaker Sanofi SA (NASDAQ: SNY) and its partner Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Wednesday secured U.S. Food and Drug Administration (FDA) approval for Dupixent (dupilumab) ...
Sanofi Leans On Dupixent For First-Quarter Beat A Week Ahead Of New CEO
Sanofi stock jumped early Thursday on strong first-quarter sales and earnings, with new CEO Belen Garijo set to take the reins next week.
Sanofi Faces Revenue Replacement Challenge After Dupixent Patent Expiry
Sanofi Faces Revenue Replacement Challenge After Dupixent Patent Expiry
Sanofi Earnings Call Transcript: Q1 2026
Q1 2026 saw 13.6% sales growth and 14% EPS growth, led by Dupixent and new launches. Guidance for high single-digit sales growth in 2026 is maintained, with strong performance in rare diseases and vaccines, and robust capital allocation for future BD/M&A.
Sanofi (SNY) Exceeds Q1 Expectations with Robust Sales and EPS Growth
Sanofi (SNY) Exceeds Q1 Expectations with Robust Sales and EPS Growth
Sanofi (SNY) and Regeneron (REGN) Gain U.S. Approval for Dupixent in Young Children
Sanofi (SNY) and Regeneron (REGN) Gain U.S. Approval for Dupixent in Young Children
Sanofi (SNY) Q1 Earnings Exceed Expectations with Strong Sales Growth
Sanofi (SNY) Q1 Earnings Exceed Expectations with Strong Sales Growth
Sanofi SA Profit Falls In Q1
PARIS (dpa-AFX) - Sanofi SA (SNY) announced earnings for first quarter that Dropped, from last yearThe company's earnings came in at EUR1.61 billion, or EUR1.34 per share. This compares with EUR1....
Sanofi Posts Higher Sales Amid Leadership Transition
Sales rose 14% to €10.51 billion at constant currency, boosted by new launches and recent acquisitions.
Sanofi Q1 Business Net Income Rises; Reiterates 2026 Guidance
(RTTNews) - Sanofi (SNY, SAN.PA) reported that its first quarter net income from continuing operations declined to 1.59 billion euros from 1.72 billion euros, prior year. Basic earnings per share from...